Molecular markers associated with response to chemotherapy in gastroentero-pancreatic neuroendocrine tumors

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 847-856

  O'Toole, Dermot ^a,b   Couvelard, Anne ^b,c   Rebours, Vinciane ^b   Zappa, Magali ^b   Hentic, Olivia ^b   Hammel, Pascal ^b   Levy, Philippe ^b   Bedossa, Pierre ^b,c   Raymond, Eric ^b   Ruszniewski, Philippe ^b  

^a ST JAMES S HOSPITAL   (Ireland)

^b BEAUJON HOSPITAL   (France)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; KI 67 ANTIGEN; MOLECULAR MARKER; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN BCL 2; PROTEIN CA9; PROTEIN HLMH1; PROTEIN KINASE B; PROTEIN MUTL; PROTEIN P53; STREPTOZOCIN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CORRELATION ANALYSIS; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS TUMOR; PROGNOSIS; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 78649819705     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0204     Document Type: Article

References (34)

1. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF & Schilsky RL 2009 American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. Journal of Clinical Oncology 27 2091-2096. (doi:10.1200/JCO.2009.21.9170)
2. Bendardaf R, Lamlum H, Ristamaki R, Syrjanen K & Pyrhonen S 2008 Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncology Reports 20 999-1004. (doi:10.3892/or-00000101)
3. Blanco-Aparicio C, Renner O, Leal JF & Carnero A 2007 PTEN more than the AKT pathway. Carcinogenesis 28 1379-1386. (doi:10.1093/carcin/bgm052)
4. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV & Papotti M 2008 Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clinical Cancer Research 14 1059-1064. (doi:10.1158/1078-0432.CCR-07-1513)
5. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K et al. 2005 Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer 92 94-101. (doi:10.1038/sj.bjc.6602245)
6. Couvelard A, Hu J, Steers G, O'Toole D, Sauvanet A, Belghiti J, Bedossa P, Gatter K, Ruszniewski P & Pezzella F 2006 Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology 131 1597-1610. (doi:10.1053/j.gastro.2006.09.007)
7. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P & Bedossa P 2008 Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clinical Cancer Research 14 6634-6639. (doi:10.1158/1078-0432. CCR-07-5258)
8. Dhawan P, Singh AB, Ellis DL & Richmond A 2002 Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kB and tumor progression. Cancer Research 62 7335-7342.
9. Dowsett M & Dunbier AK 2008 Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clinical Cancer Research 14 8019-8026. (doi:10.1158/1078-0432.CCR-08-0974)
10. Harpole DH Jr, Moore MB, Herndon JE II, Aloia T, D'Amico TA, Sporn T, Parr A, Linoila I & Allegra C 2001 The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clinical Cancer Research 7 562-569.
11. Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WN et al. 2009 Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. Journal of Clinical Oncology 27 2129-2136. (doi:10.1200/JCO.2008.18. 8623)
12. Huang WC & Hung MC 2009 Induction of akt activity by chemotherapy confers acquired resistance. Journal of the Formosan Medical Association 108 180-194. (doi:10.1016/S0929-6646(09)60051-6)
13. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S & Wada H 2000 Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. International Journal of Oncology 17 47-54.
14. Ide T, Kitajima Y, Ohtaka K, Mitsuno M, Nakafusa Y & Miyazaki K 2008 Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncology Reports 19 1571-1576.
15. Kitajima Y, Miyazaki K, Matsukura S, Tanaka M & Sekiguchi M 2003 Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer. Gastric Cancer 6 86-95. (doi:10.1007/s10120-003- 0213-z)
16. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS et al. 2009 O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clinical Cancer Research 15 338-345. (doi:10.1158/1078-0432.CCR-08-1476)
17. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C & Solcia E 2009 Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Human Pathology 40 30-40. (doi:10.1016/j.humpath.2008.06.005)
18. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E et al. 2009 PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology 27 2622-2629. (doi:10.1200/JCO.2008.20.2796)
19. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W & Lenz HJ 2009 Thymidylate synthase gene variations: predictive and prognostic markers. Molecular Cancer Therapeutics 8 1000-1007. (doi:10.1158/1535-7163.MCT-08-0219)
20. Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K, Giangrande PH, Dewhirst MW et al. 2008 RNA aptamer-targeted inhibition of NF-κB suppresses nonsmall cell lung cancer resistance to doxorubicin. Molecular Therapy 16 66-73. (doi:10.1038/sj.mt.6300320)
21. Miglietta L, Vanella P, Canobbio L, Parodi MA, Guglielmini P & Boccardo F 2009 Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, her2 status, grading and ki-67 proliferation index. Anticancer Research 29 1621-1625.
22. Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N & Miki T 2001 Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92 510-518. (doi:10.1002/1097-0142(20010801) 92:3〈510::AID-CNCR1349〉3.0.CO;2-0)
23. Modok S, Mellor HR & Callaghan R 2006 Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Current Opinion in Pharmacology 6 350-354. (doi:10.1016/j.coph.2006.01.009)
24. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC & Meric-Bernstam F 2008 Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer 15 257-266. (doi:10.1677/ERC-07-0202)
25. O'Toole D 2006 Current trend: endocrine tumors of the stomach, small bowel, colon and rectum. Gastroenterologie Clinique et Biologique 30 276-291. (doi:10.1016/S0399-8320(06)73165-7)
26. O'Toole D, Hentic O, Corcos O & Ruszniewski P 2004 Chemotherapy for gastro-enteropancreatic endocrine tumours. Neuroendocrinology 80 (Supplement 1) 79-84. (doi:10.1159/000080747)
27. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G & Wiedenmann B 2008 Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113 256-265. (doi:10.1002/cncr.23549)
28. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU & Eng C 2000 Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. American Journal of Pathology 157 1097-1103.
29. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ et al. 1997 Prognostic importance of thymidylate synthase expression in early breast cancer. Journal of Clinical Oncology 15 1923-1931.
30. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 449 395-401. (doi:10.1007/s00428-006-0250-1)
31. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 451 757-762. (doi:10.1007/s00428-007-0452-1)
32. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J et al. 2008 Consensus guidelines for the management of patients with liver metastases from digestive (neuro)-endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 47-62. (doi:10.1159/000111037)
33. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK et al. 2009 The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer 100 405-411. (doi:10.1038/sj.bjc. 6604844)
34. Wang L, Ignat A & Axiotis CA 2002 Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Applied Immunohistochemistry and Molecular Morphology 10 139-146. (doi:10.1097/00022744-200206000-00008)